238 related articles for article (PubMed ID: 7999817)
1. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.
Hanslik TM; Newman L; Tessman M; Morrissey AB; Friedlander MA
Adv Perit Dial; 1994; 10():158-62. PubMed ID: 7999817
[TBL] [Abstract][Full Text] [Related]
2. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcus aureus CAPD-related infections are associated with nasal carriage.
Lye WC; Leong SO; van der Straaten J; Lee EJ
Adv Perit Dial; 1994; 10():163-5. PubMed ID: 7999818
[TBL] [Abstract][Full Text] [Related]
4. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
Cavdar C; Zeybel M; Atay T; Sifil A; Sanlidag C; Gulay Z; Camsari T
Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
Thodis E; Passadakis P; Panagoutsos S; Bacharaki D; Euthimiadou A; Vargemezis V
Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
[TBL] [Abstract][Full Text] [Related]
6. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.
Lobbedez T; Gardam M; Dedier H; Burdzy D; Chu M; Izatt S; Bargman JM; Jassal SV; Vas S; Brunton J; Oreopoulos DG
Nephrol Dial Transplant; 2004 Dec; 19(12):3140-3. PubMed ID: 15466881
[TBL] [Abstract][Full Text] [Related]
7. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
Uttley L; Vardhan A; Mahajan S; Smart B; Hutchison A; Gokal R
J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524
[TBL] [Abstract][Full Text] [Related]
8. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis.
Kingwatanakul P; Warady BA
Adv Perit Dial; 1997; 13():281-4. PubMed ID: 9360700
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage.
Doebbeling BN; Reagan DR; Pfaller MA; Houston AK; Hollis RJ; Wenzel RP
Arch Intern Med; 1994 Jul; 154(13):1505-8. PubMed ID: 8018006
[TBL] [Abstract][Full Text] [Related]
10. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients.
Blowey DL; Warady BA; McFarland KS
Adv Perit Dial; 1994; 10():297-9. PubMed ID: 7999849
[TBL] [Abstract][Full Text] [Related]
11. Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients.
Lederer SR; Riedelsdorf G; Schiffl H
Eur J Med Res; 2007 Jul; 12(7):284-8. PubMed ID: 17933699
[TBL] [Abstract][Full Text] [Related]
12. Safety of targeted perioperative mupirocin treatment for preventing infections after cardiac surgery.
Shrestha NK; Banbury MK; Weber M; Cwynar RE; Lober C; Procop GW; Karafa MT; Gordon SM
Ann Thorac Surg; 2006 Jun; 81(6):2183-8. PubMed ID: 16731151
[TBL] [Abstract][Full Text] [Related]
13. Elimination of Staphylococcus aureus in hemodialysis patients.
Bommer J; Vergetis W; Andrassy K; Hingst V; Borneff M; Huber W
ASAIO J; 1995; 41(1):127-31. PubMed ID: 7727815
[TBL] [Abstract][Full Text] [Related]
14. [Use of nasal mupirocin for Staphylococcus aureus: effect on nasal carriers and nosocomial infections].
García AM; Villa MV; Escudero ME; Gómez P; Vélez MM; Múnera MI; Franco G
Biomedica; 2003 Jun; 23(2):173-9. PubMed ID: 12872556
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiology and prevention of Staphylococcus aureus infections during hemodialysis].
Boelaert JR; Van Landuyt HW; De Baere YA; Gheyle DW; Daneels RF; Schurgers ML; Matthys EG; Gordts BZ
Nephrologie; 1994; 15(2):157-61. PubMed ID: 8047204
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.
Pérez-Fontán M; Rosales M; Rodríguez-Carmona A; Moncalián J; Fernández-Rivera C; Cao M; Valdés F
Adv Perit Dial; 1992; 8():242-5. PubMed ID: 1361797
[TBL] [Abstract][Full Text] [Related]
17. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates.
Paterson DL; Rihs JD; Squier C; Gayowski T; Sagnimeni A; Singh N
Transplantation; 2003 Jan; 75(2):194-8. PubMed ID: 12548122
[TBL] [Abstract][Full Text] [Related]
18. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis.
Cavdar C; Atay T; Zeybel M; Celik A; Ozder A; Yildiz S; Gulay Z; Camsari T
Adv Perit Dial; 2004; 20():67-70. PubMed ID: 15384798
[TBL] [Abstract][Full Text] [Related]
19. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
Cavdar C; Saglam F; Sifil A; Celik A; Atay T; Gungor O; Ozder A; Gulay Z; Camsari T
Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916
[TBL] [Abstract][Full Text] [Related]
20. Controlling the usage of intranasal mupirocin does impact the rate of Staphylococcus aureus deep sternal wound infections in cardiac surgery patients.
Nicholson MR; Huesman LA
Am J Infect Control; 2006 Feb; 34(1):44-8. PubMed ID: 16443093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]